Publicaciones (43) Publicaciones de BENITO VELAYOS JIMENEZ

2022

  1. Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)

    Clinical Gastroenterology and Hepatology, Vol. 20, Núm. 10, pp. 2243-2257

  2. Endoscopic treatment of perforation using a Padlock Clip®: 2 case reports

    Gastroenterologia y Hepatologia, Vol. 45, pp. 99-100

  3. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

  4. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2021

  1. Hydration with Lactated Ringer's solution combined with rectal diclofenac in the prevention of pancreatitis after endoscopic retrograde cholangiopancreatography

    Gastroenterologia y Hepatologia, Vol. 44, Núm. 1, pp. 20-26

  2. Prevalencia y factores asociados a la mala calidad del sueño en pacientes con enfermedad inflamatoria intestinal no hospitalizados

    Revista Española de Enfermedades Digestivas, Vol. 113, Núm. 7, pp. 512-518

  3. Rare pancreatic cyst: lymphangioma

    Gastroenterologia y Hepatologia, Vol. 44, Núm. 10, pp. 726-727

  4. Should the birth month be considered as one of the possible environmental risk factors in the pathogenesis of inflammatory bowel disease?

    European Journal of Gastroenterology and Hepatology

2020

  1. Immune thrombocytopenic purpura associated with inactive ulcerative colitis in chronic treatment with adalimumab

    Gastroenterologia y Hepatologia, Vol. 43, Núm. 1, pp. 28-29

2019

  1. Immunomodulatory Therapy Does Not Increase the Risk of Cancer in Persons With Inflammatory Bowel Disease and a History of Extracolonic Cancers

    The American journal of gastroenterology, Vol. 114, Núm. 5, pp. 771-776

  2. Increased risk of thiopurine-related adverse events in elderly patients with IBD

    Alimentary Pharmacology and Therapeutics, Vol. 50, Núm. 7, pp. 780-788

2018

  1. Non-visible colovesical fistula located by cystoscopy and successfully managed with the novel Padlock® device for endoscopic closure

    International Journal of Colorectal Disease, Vol. 33, Núm. 6, pp. 827-829

  2. Rectal diclofenac does not prevent post-ERCP pancreatitis in consecutive high-risk and low-risk patients

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 110, Núm. 8, pp. 505-509

2017

  1. Fístula hepatocólica tratada con el nuevo dispositivo de cierre endoscópico Padlock®

    Revista Española de Enfermedades Digestivas, Vol. 109, Núm. 10, pp. 731-733

  2. Influencia de la experiencia acumulada del explorador en el valor predictivo negativo de la cápsula endoscópica

    Gastroenterologia y Hepatologia, Vol. 40, Núm. 1, pp. 10-15

  3. Tuberculosis, one more consideration in the differential diagnosis of a pancreatic mass

    Gastroenterologia y Hepatologia, Vol. 40, Núm. 9, pp. 619-621

2016

  1. Etiología y prevalencia de los cánceres colorrectales poscolonoscopia

    Gastroenterologia y Hepatologia, Vol. 39, Núm. 10, pp. 647-655

  2. Fístulas ileocólicas tras radioterapia por carcinoma de endometrio

    Gastroenterologia y Hepatologia, Vol. 39, Núm. 1, pp. 23-24

2015

  1. Early detection of high oxidative activity in patients with adenomatous intestinal polyps and colorectal adenocarcinoma: Myeloperoxidase and oxidized low-density lipoprotein in serum as new markers of oxidative stress in colorectal cancer

    Laboratory Medicine, Vol. 46, Núm. 2, pp. 123-135

  2. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments

    Alimentary Pharmacology and Therapeutics, Vol. 41, Núm. 8, pp. 768-775